3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic

Details 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic

1992-05-21

1994-10-11

Daus, Donald G.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

A61K 3147

Patent

active

053548647

ABSTRACT:
The present invention provides a compound having the structure: ##STR1## wherein R.sup.1 and R.sup.2 are independently the same or different and are hydrogen, an acetyl group; an acyl group having the formula --CO(CH.sub.2).sub.n COCH.sub.3, wherein n=1-3; --CO(CH.sub.2).sub.n COOM, wherein n=1-4 and M is hydrogen, Na or K; or --(CH.sub.2).sub.n COOR, wherein n=1-4 and R is hydrogen, Na, K or an alkyl group having 1 to 5 carbon atoms; a hydroxyalkyl group having the formula --(CH.sub.2).sub.n CH.sub.2 OH, wherein n=1-4; a halo alkyl group having the formula --(CH.sub.2).sub.n CH.sub.2 X, wherein n=1-4 and X is a chloro, bromo, or iodo group; a metal sulfonate (--SO.sub.3 M) wherein M is Na or K; a metal sulfinate (--SO.sub.2 M) wherein M is Na or K; a alkyl sulfonate (--SO.sub.3 R) wherein R is an alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl or i-propyl; an alkylsulfonyl group (--SO.sub.2 R) wherein R is an alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl or i-propyl; a metal alkylsulfonate having the formula --(CH.sub.2).sub.n SO.sub.3 M wherein n=2-3 and M is Na or K; a metal alkylsulfate having the formula --(CH.sub.2).sub.n OSO.sub.3 M wherein n=2-3, and M is Na or K; or a .beta.-alanyl group.
The present invention also provides a process for synthesizing the above-identified compound, intermediate compounds produced thereby, a pharmaceutical composition comprising the above compounds as well as a method for inhibiting growth of tumor cells using these compounds.

REFERENCES:
patent: 2419200 (1947-04-01), Burckhalter
patent: 4603125 (1986-07-01), Atwell et al.
patent: 4704397 (1987-11-01), Fisher et al.
patent: 4815447 (1989-03-01), Mills
patent: 4815448 (1989-03-01), Mills
patent: 5229395 (1993-07-01), Watanabe et al.
Watanabe et al, NIH Grant Request, Award CA-18856 approved, 1990.
Mills et al Chem. Abstr vol. 116 entry 37120d (1991).
Cain et al. Jour. Med. Chem. vol. 19, pp. 1124-1129 (1976).
Ferguson et al, Jour. Med. Chem. vol. 22 pp. 251-255 (1979).
Cain et al., Potential Antitumor Agents. 11. 9-Anilinoacridines, J. Med. Chem (1971), vol. 14, pp. 311-315.
Cain et al., Potential Antitumor Agents. 16.4'-(Acridin-9-ylamino) methanesulfonanilides, J. Med. Chem. (1975), vol. 18, pp. 1110-1117.
Corbett et al., Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas, Cancer, (1977), vol. 40, pp. 2660-2680.
Goldin et al., Current Results of the Screening Program at the Division of Cancer Treatment, National Cancer Institute, Eur. J. Cancer, (1981) vol. 17, pp. 129-142.
Legha et al., 4'(9'-Acridinylamino) methanesulfon-m-anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute Leukemia, Ann. Internal. Med., (1980), vol. 93 (Part I), pp. 17-21.
Cabanillas et al., Initial Experience with AMSA as Single Agent Treatment Against Malignant Lymphoproliferative Disorders, Blood, (1981) vol. 57, pp. 614-616.
Arlin et al., Phase I and II Trial of 4'(9-Acridinylamino) methanesulfon-m anisidide in Patients with Acute Leukemia, Cancer Res., (1980), vol. 40 pp. 3304-3306.
Laster et al., Therapeutic Synergism (TS) of N-(4-9-Acridinylamino)-3-methoxyphenyl) methanesulfonamide (m-AMSA) or 1, 4-Dihydroxy-5, 8-bis [[2-Hydroxyethyl]Amino]-9, 10-Anthracenedione (DiOHA) Plus cis-Diamminedichloroplatinum (cis-DDPt) Against P338/O Leukemia, Proc. Am. Ass. Res., (1980), vol. 21, p. 271, abstract 1086.
Caspar et al., Phase II Evaluation of 4'(9-Acridinylamino)-methansulfonanisidide (AMSA) in Patients with Non-Small Lung Cancer, Cancer Treat. Rep., (1980), vol. 64, pp. 345-347.
Nelson et al., Mechanism of Antitumor Drug Action: Poisoning of Mammalian DNA Topoisomerase II on DNA by 4'(9-Acridinylamino)-methanesulfon-m-anisidide, Proc. Natl. Acad. Sci USA, (Mar., 1984), vol. 81, pp. 1361-1365.
Pommier et al., Correlations between Intercalator-induced DNA Strand Breaks and Sister Chromatid Exchanges, Mutations, and Cytoxicity in Chinese Hamster Cells, Cancer Res., (1985), vol. 45, pp. 3143-3149.
Wilson et al., Comparison of the Mutagenic and Clastogenic Activity of Amsacrine and other DNA-Intercalating Drugs in Cultured V79 Chinese Hamster Cells, Cancer Res., (1984), vol. 44, pp. 4420-4431.
Khan et al., Mechanism of the Hydrolysis of m-AMSA (NSC 249992), Proc. Am. Ass. Cancer Res., (1980), vol. 21, p. 306, Abstract No. 1227.
Shoemaker et al., Identification of the Principal Biliary Metabolite of 4'-(9-Acridinylamino)-methanesulfon-m-anisidide in rats, Drug Metab. Disp., (1982), vol. 10, pp. 35-39.

Affiliated with

Also associated with

Rating

3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as antic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1659596